WOODINVILLE, WA--(Marketwire - April 03, 2009) - Eden Bioscience Corporation (NASDAQ: EDEN)
today announced that it has filed with the Securities and Exchange
Commission ("SEC"), and commenced mailing to shareholders, its definitive
proxy statement for the special meeting of shareholders to vote for
approval of the voluntary dissolution and liquidation of the Company. The
definitive proxy statement is being mailed to all Company shareholders of
record as of March 23, 2009. The special meeting of shareholders will be
held at 9 a.m., Pacific time, on May 20, 2009, at the Country Inn & Suites
By Carlson located at 19333 North Creek Parkway in Bothell, Washington.
On December 5, 2008, the Company announced that its Board of Directors
determined, in its best business judgment after consideration of available
strategic options, that it is in the best interests of the Company and its
shareholders to liquidate the Company's assets and to dissolve the Company
and had approved a plan of complete dissolution and liquidation of the
Company (the "Plan"), subject to shareholder approval. The Board of
Directors unanimously recommends that the Company's shareholders vote for
approval of the Plan.
IMPORTANT ADDITIONAL INFORMATION FILED WITH THE SEC
This press release is for informational purposes only. It is neither a
solicitation of a proxy, an offer to purchase, nor a solicitation of an
offer to sell shares of Eden Bioscience Corporation. In connection with
the proposed Plan, the Company filed with the SEC a definitive proxy
statement and other relevant materials. THE COMPANY'S SHAREHOLDERS ARE
URGED TO READ THE DEFINITIVE PROXY STATEMENT AND THE OTHER RELEVANT
MATERIALS FILED WITH THE SEC BECAUSE THEY CONTAIN IMPORTANT INFORMATION
ABOUT THE COMPANY AND THE PLAN. Shareholders may obtain a free copy of the
definitive proxy statement and the other relevant materials, and any other
documents filed by the Company with the SEC, at the SEC's web site at
http://www.sec.gov. In addition, on April 2, 2009, the Company commenced
mailing of the definitive proxy statement to shareholders of record on
March 23, 2009, the record date for the special meeting. A free copy of
the definitive proxy statement and other documents filed with the SEC by
the Company may also be obtained by directing a written request to: Eden
Bioscience Corporation, Attn: Secretary, 14522 NE North Woodinville Way,
Suite 202B, Woodinville, Washington 98072, or accessing the "About Us --
Investor Information" section of the Company's website at
http://www.edenbio.com.
The Company and its executive officer and directors may be deemed to be
participants in the solicitation of proxies from the Company's shareholders
with respect to the proposed Plan. Information regarding their direct or
indirect interests, by security holdings or otherwise, in the solicitation
is included in the definitive proxy statement filed by the Company with the
SEC.
